<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04727138</url>
  </required_header>
  <id_info>
    <org_study_id>EXS21546-001</org_study_id>
    <nct_id>NCT04727138</nct_id>
  </id_info>
  <brief_title>3-part Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of EXS21546</brief_title>
  <official_title>3-part Study to Assess Safety, Tolerability, PK and PD of Single and Multiple Ascending Doses of EXS21546, and to Evaluate the Relative Bioavailability of 2 Formulations, in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Exscientia Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Quotient Sciences</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Exscientia Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A 3-part Study to Assess Safety, Tolerability, PK and PD of Single (Part 1) and Multiple&#xD;
      (Part 2) Ascending Doses of EXS21546, and to Evaluate the Relative Bioavailability of a Solid&#xD;
      Dose Formulation Compared to a Powder for Oral Suspension (Part 3), in Healthy Male Subjects.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Part 1 is a randomised, double-blind, placebo-controlled, SAD study with a food effect&#xD;
      assessment.&#xD;
&#xD;
      Part 2 is a randomised, double-blind, placebo controlled, MAD study over 14 days. In order to&#xD;
      explore the potential CYP3A4 inducer effect, midazolam will also be administered in one&#xD;
      cohort.&#xD;
&#xD;
      Part 3 is a 3-period, open label, randomised, sequential study. Each subject will receive&#xD;
      solid dose formulation and powder for oral suspension in a randomised manner.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 8, 2020</start_date>
  <completion_date type="Anticipated">December 23, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 23, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Part 1 and Part 2 are double blind. Part 3 is open label.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with treatment emergent Adverse Events</measure>
    <time_frame>1 month</time_frame>
    <description>Number of participants with treatment emergent Adverse Events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>EXS21546 and Metabolite Area under the plasma concentration versus time curve (AUC)</measure>
    <time_frame>17 days</time_frame>
    <description>EXS21546 and Metabolite Area under the plasma concentration versus time curve (AUC)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>EXS21546 and Metabolite Peak Plasma Concentration (Cmax)</measure>
    <time_frame>17 days</time_frame>
    <description>EXS21546 and Metabolite Peak Plasma Concentration (Cmax)</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">84</enrollment>
  <condition>Oncology</condition>
  <arm_group>
    <arm_group_label>EXS21546 Powder for Oral Suspension</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>EXS21546 Powder for Oral Suspension</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo Powder for Oral Suspension</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EXS21546 Granule in Capsule</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>EXS21546 Granule in Capsule</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EXS21546 Powder for Oral Suspension</intervention_name>
    <description>EXS21546 Powder for Oral Suspension</description>
    <arm_group_label>EXS21546 Powder for Oral Suspension</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EXS21546 Granule in Capsule</intervention_name>
    <description>EXS21546 Granule in Capsule</description>
    <arm_group_label>EXS21546 Granule in Capsule</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Midazolam</intervention_name>
    <description>Interaction</description>
    <arm_group_label>EXS21546 Powder for Oral Suspension</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Food Effect</intervention_name>
    <description>Fed/Fasted</description>
    <arm_group_label>EXS21546 Granule in Capsule</arm_group_label>
    <arm_group_label>EXS21546 Powder for Oral Suspension</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo Powder for Oral Suspension</intervention_name>
    <description>Placebo Powder for Oral Suspension</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  BMI 18.0 to 30.0 kg/m2&#xD;
&#xD;
          -  Weight â‰¥60 kg&#xD;
&#xD;
          -  Must adhere to contraception requirements&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects who have received any IMP in a clinical research study within the 90 days&#xD;
             prior to Day 1&#xD;
&#xD;
          -  Subjects who have previously been administered IMP in this study.&#xD;
&#xD;
          -  Evidence of current SARS-CoV-2 infection&#xD;
&#xD;
          -  History of any drug or alcohol abuse in the past 2 years&#xD;
&#xD;
          -  Regular alcohol consumption in males &gt;21 units per week&#xD;
&#xD;
          -  A confirmed positive alcohol breath test at screening or admission&#xD;
&#xD;
          -  Current smokers and those who have smoked within the last 12 months. A confirmed&#xD;
             breath carbon monoxide reading of greater than 10 ppm at screening or admission&#xD;
&#xD;
          -  Current users of e-cigarettes and nicotine replacement products and those who have&#xD;
             used these products within the last 12 months&#xD;
&#xD;
          -  Subjects with pregnant or lactating partners&#xD;
&#xD;
          -  Positive hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCV Ab) or&#xD;
             human immunodeficiency virus (HIV) antibody results&#xD;
&#xD;
          -  Regimen L only: History of sleep apnea&#xD;
&#xD;
          -  Subjects with a history of cholecystectomy or gall stones&#xD;
&#xD;
          -  Serious adverse reaction or serious hypersensitivity to any drug or the formulation&#xD;
             excipients&#xD;
&#xD;
          -  Presence or history of clinically significant allergy requiring treatment, as judged&#xD;
             by the investigator. Hay fever is allowed unless it is active&#xD;
&#xD;
          -  Donation of blood or plasma within the previous 3 months or loss of greater than 400&#xD;
             mL of blood&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Phillip Evans</last_name>
    <role>Principal Investigator</role>
    <affiliation>Quotient Sciences Principal Investigator</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Holly Garratt</last_name>
    <phone>01865 818941</phone>
    <email>hgarratt@exscientia.co.uk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Quotient Sciences</name>
      <address>
        <city>Nottingham</city>
        <zip>NG11 6JS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Phillip Evans</last_name>
      <phone>0330 330 0000</phone>
      <email>volunteer@quotientsciences.com</email>
    </contact>
    <contact_backup>
      <last_name>Michelle Lawton</last_name>
      <phone>0115 974 9000</phone>
      <email>Michelle.Lawton@quotientsciences.com</email>
    </contact_backup>
    <investigator>
      <last_name>Phillip Evans</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>December 23, 2020</study_first_submitted>
  <study_first_submitted_qc>January 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 27, 2021</study_first_posted>
  <last_update_submitted>October 20, 2021</last_update_submitted>
  <last_update_submitted_qc>October 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Midazolam</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

